TNBC may respond to blood cancer Multiple Myeloma Drug

Cancer cell has an interesting new paper, very early stages of course:

http://www.healthcanal.com/cancers/breast-cancer/41802-aggressive-triple-negative-breast-cancers-may-be-sensitive-to-drugs-that-clog-their-waste-disposal.html


Quote: 
By selectively turning genes off throughout the genomes of triple-negative tumor cells in vitro, Lieberman's team found that these cells absolutely require active proteasomes in order to live. When turned off, the cells die. 

These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade®), a proteasome inhibitor that revolutionized the care of patients with the blood cancer multiple myeloma.